<DOC>
	<DOCNO>NCT00790699</DOCNO>
	<brief_summary>The purpose study determine whether inject Symlin insulin multiple injection port safe effective . This measure HbA1c value take begin study final visit . The secondary objective study measure patient satisfaction toward use multiple injection port .</brief_summary>
	<brief_title>Safety Study Using Symlin Alongside Insulin Multiple Injection Port</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>male female age 18 utilizing regimen least two injection daily insulin least two injection daily Symlin able understand sign inform consent form HIPPA form agree study visit procedure HbA1c &gt; 6.5 &lt; 9.0 ( inclusive ) history current diagnosis chronic disease view PI would interfere adequate involvement completion requirement study history malignancy last five year study entry ( basal cell carcinoma ) current use drug alter gastrointestinal motility ( e.g. , anticholinergic agent atropine ) , agent slow intestinal absorption nutrient ( e.g . aglucosidase inhibitor ) promotility agent ( e.g . metachlopromide ) contraindication Symlin IPORT accord package label female pregnant , lactate plan become pregnant duration trial poorly compliant current insulin and/or Symlin regimen , define HCP history know hypersensitivity plastic polymer treatment investigational drug within one month prior enrollment myocardial infarction stroke within six month prior screen initiate use Symlin pen Insulin pen lieu vial last 4 week ( pen use okay long use least 4 week prior screen visit ) female subject childbearing potential practicing inadequate birth control ( adequate birth control define use oral contraceptive , double barrier method , Intrauterine device , surgical sterilization vasectomize partner ) confirm diagnosis gastroparesis hypoglycemia unawareness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>diabetes</keyword>
	<keyword>Symlin</keyword>
	<keyword>pramlintide acetate</keyword>
	<keyword>insulin</keyword>
	<keyword>multiple injection port</keyword>
	<keyword>I-PORT</keyword>
</DOC>